Blood Pressure Regulation: Baroreflex, RAAS and ADH

Short-term neural control (baroreceptors, vasomotor centre) vs long-term hormonal control (RAAS cascade, ADH, ANP). Drug targets: ACE inhibitors, ARBs, beta-blockers, with veterinary-specific clinical applications.

Introduction: Why Blood Pressure Must Be Regulated

Arterial blood pressure is the product of cardiac output and total peripheral resistance. It must be maintained within a narrow range: too low, and the brain and kidneys are hypoperfused; too high, and the delicate microvasculature of the retina, kidney, and brain is damaged. The body employs a layered defence — rapid, neurally mediated reflexes that correct pressure in seconds; slower, hormonally mediated systems that adjust blood volume and vascular tone over hours to days; and long-term renal mechanisms that set the chronic pressure level.

This article dissects the short-term baroreflex, the intermediate-term renin-angiotensin-aldosterone system and antidiuretic hormone, and the counter-regulatory atrial natriuretic peptide — weaving them into a unified model of blood pressure control that directly informs clinical management of hypotension and hypertension in veterinary patients.

The Baroreflex: Neural Control in Seconds

Baroreceptors — The Pressure Sensors

Baroreceptors are stretch-sensitive nerve endings located in the carotid sinus (at the bifurcation of the common carotid artery, innervated by the glossopharyngeal nerve, CN IX) and the aortic arch (innervated by the vagus nerve, CN X). They are NOT pressure sensors in the abstract — they are STRETCH sensors. When arterial pressure rises, the vessel wall stretches → baroreceptor firing rate increases. When pressure falls, stretch decreases → firing rate decreases.

Baroreceptors fire continuously at normal pressures (~50–80 impulses/second at MAP 100 mmHg). They are MOST sensitive to CHANGES in pressure (the dynamic sensitivity — they fire more during the rising phase of the pressure pulse than during the falling phase at the same absolute pressure) and adapt ('reset') to sustained pressure changes within 1–2 days. This adaptation is why the baroreflex is a short-term regulator — it cannot defend against chronic hypertension or hypotension.

The Vasomotor Centre — The Integration Hub

Baroreceptor afferents synapse in the nucleus tractus solitarius (NTS) in the medulla. The NTS integrates baroreceptor input and projects to: (1) The caudal ventrolateral medulla (CVLM) → inhibits the rostral ventrolateral medulla (RVLM) → reduced sympathetic outflow. (2) The nucleus ambiguus and dorsal motor nucleus of the vagus → increased parasympathetic (vagal) outflow. The net effect of baroreceptor activation: INHIBITION of sympathetic outflow, STIMULATION of parasympathetic outflow → reduced heart rate (↓ SA node firing), reduced contractility (↓ β1), vasodilation (↓ α1 on arterioles), and venodilation (↓ α1 on veins → reduced venous return → reduced preload). The baroreflex arc is completed in <1–2 seconds — faster than any hormonal system.

The Renin-Angiotensin-Aldosterone System (RAAS): Long-Term Control

The RAAS Cascade — Step by Step

1. RENIN RELEASE: The juxtaglomerular (JG) cells in the afferent arteriole of the kidney release renin in response to three stimuli: (a) reduced renal perfusion pressure (detected by the JG cells themselves — they are intrarenal baroreceptors), (b) reduced NaCl delivery to the macula densa (in the distal tubule — tubuloglomerular feedback), and (c) increased sympathetic nerve activity (β1 receptors on JG cells). Renin is a proteolytic enzyme — it cleaves angiotensinogen (a large plasma protein produced by the liver) into angiotensin I (a decapeptide, biologically inert).
2. ACE (angiotensin-converting enzyme): Located primarily on the surface of pulmonary capillary endothelial cells, ACE cleaves two amino acids from angiotensin I → angiotensin II (an octapeptide, the primary effector hormone of the RAAS). ACE also degrades bradykinin (a potent vasodilator) — this is why ACE inhibitors cause a dry cough in some patients (bradykinin accumulation).
3. Angiotensin II actions: (a) POTENT VASOCONSTRICTION — directly on vascular smooth muscle (AT1 receptor → Gq → IP3/DAG → Ca²⁺ release → contraction). (b) ALDOSTERONE SECRETION — stimulates the adrenal zona glomerulosa → aldosterone → increased Na⁺ reabsorption (and K⁺ secretion) in the distal nephron → water retention → increased blood volume. (c) ADH RELEASE — stimulates the posterior pituitary → ADH → increased water reabsorption in the collecting duct (aquaporin-2 insertion) → water retention. (d) THIRST — stimulates the subfornical organ (circumventricular organ, outside the blood-brain barrier) → increased water intake. (e) Sympathetic potentiation — facilitates noradrenaline release from sympathetic nerve terminals. (f) TGF-β and PAI-1 production → promotes cardiac and renal fibrosis (the 'bad' side of chronic RAAS activation).

Antidiuretic Hormone (ADH / Vasopressin) and Atrial Natriuretic Peptide (ANP)

ADH — The Water-Retaining, Vasoconstricting Hormone

ADH (arginine vasopressin) is a nonapeptide synthesised in the supraoptic and paraventricular nuclei of the hypothalamus and released from the posterior pituitary. TWO STIMULI: (1) Increased plasma osmolality (detected by hypothalamic osmoreceptors — as little as a 1% increase in osmolality triggers ADH release). This is the dominant stimulus. (2) Decreased blood volume/pressure (detected by baroreceptors — a 5–10% drop in blood volume is required, making this a less sensitive but more powerful stimulus). TWO RECEPTOR TYPES: (1) V1 receptors (vascular smooth muscle) → vasoconstriction (IP3/DAG → Ca²⁺). (2) V2 receptors (renal collecting duct) → cAMP → aquaporin-2 insertion into the apical membrane → increased water permeability → water reabsorption → concentrated urine. Clinical significance: ADH is used as a vasopressor in vasodilatory shock (sepsis) unresponsive to catecholamines — it restores vascular tone via V1 receptors.

ANP — The Brake on RAAS

Atrial natriuretic peptide (ANP) is a 28-amino-acid peptide synthesised, stored, and released by atrial myocytes in response to ATRIAL STRETCH (increased blood volume → increased atrial filling pressure → stretch). ANP acts as an endogenous brake on the RAAS: (1) Vasodilation (cGMP-mediated relaxation of vascular smooth muscle). (2) Natriuresis and diuresis (increased GFR — afferent arteriole dilation + efferent arteriole constriction; decreased Na⁺ reabsorption in the collecting duct). (3) Inhibition of renin release (direct effect on JG cells). (4) Inhibition of aldosterone secretion (direct effect on adrenal zona glomerulosa). (5) Inhibition of ADH secretion. B-type natriuretic peptide (BNP), released primarily by ventricular myocytes in response to VENTRICULAR STRETCH, has similar effects. NT-proBNP (the N-terminal fragment of proBNP) is the clinical biomarker — elevated in dogs and cats with significant heart disease (myocardial stretch). It is used to differentiate cardiac from respiratory causes of dyspnoea.

Drug Targets in Blood Pressure Regulation

Clinical Scenarios: Applying the Physiology

Feline Systemic Hypertension

Cats — unlike humans and dogs — RARELY develop primary ('essential') hypertension. The vast majority of hypertensive cats have an identifiable underlying disease: chronic kidney disease (~60% of cases), hyperthyroidism (~20%), or hyperaldosteronism (rare). The pathogenesis: CKD → reduced nephron mass → impaired sodium excretion → volume expansion + RAAS activation → hypertension. Hyperthyroidism → increased β-adrenergic receptor expression → increased cardiac output → systolic hypertension. Diagnosis: systolic BP >160 mmHg on repeated measurements (Doppler method, quiet environment, acclimatised cat — 'white coat' effect can falsely elevate readings by 15–30 mmHg). Target organ damage: retinal haemorrhage/detachment (acute blindness), hypertensive encephalopathy (seizures, mentation changes), proteinuria (glomerular hypertension), left ventricular hypertrophy. Management: amlodipine 0.625–1.25 mg/cat PO q24h. If proteinuric CKD: add telmisartan or benazepril. Monitor BP weekly initially, then monthly once controlled.

Hypotension Under Anaesthesia — A Baroreflex Story

Most anaesthetic agents (inhalants — isoflurane, sevoflurane; propofol, alfaxalone) depress the baroreflex at multiple levels: they reduce sympathetic outflow from the RVLM, they impair baroreceptor sensitivity (reduced gain of the reflex), and they directly depress myocardial contractility and vascular smooth muscle tone. The result: a patient who cannot mount an appropriate compensatory response to hypovolaemia or vasodilation. Management: (1) Reduce inhalant concentration (if surgical plane allows). (2) IV fluid bolus (10–20 mL/kg balanced crystalloid) — addresses hypovolaemia component. (3) If MAP remains <60 mmHg despite adequate volume: positive inotrope/vasopressor. Options: dopamine (5–10 μg/kg/min — β1 + α1; increases CO + TPR), dobutamine (2–10 μg/kg/min — β1 selective; primarily increases CO), norepinephrine (0.1–2 μg/kg/min — α1 >> β1; primarily increases TPR in vasodilatory shock). Monitor: continuous direct arterial blood pressure (gold standard), ECG, ETCO₂, SpO₂.

The Kidney as the Long-Term Blood Pressure Regulator

Pressure Natriuresis — How the Kidney Sets the Chronic BP Level

The kidney regulates long-term blood pressure through the pressure-natriuresis mechanism: when arterial pressure rises, the kidney excretes MORE sodium and water → blood volume falls → cardiac output falls → pressure falls. When pressure falls, the kidney excretes LESS sodium and water → blood volume rises → pressure rises. This negative feedback loop sets the CHRONIC blood pressure level — the set point at which sodium intake and excretion are balanced.

In hypertension, the pressure-natriuresis curve is shifted RIGHTWARD — a higher pressure is required to excrete the same sodium load. This shift can be caused by: (1) renal disease (reduced nephron mass → reduced filtration capacity), (2) excessive RAAS activation (angiotensin II stimulates Na⁺ reabsorption in the proximal tubule), (3) excessive sympathetic nerve activity (increases renin release and directly stimulates Na⁺ reabsorption), and (4) genetic factors (mutations in renal Na⁺ transporters — e.g., Liddle syndrome from gain-of-function ENaC mutations — though rare in veterinary patients).

Clinical implication: diuretics lower blood pressure by reducing blood volume → shift the operating point leftward on the pressure-natriuresis curve. ACE inhibitors and ARBs shift the curve leftward by reducing angiotensin II-mediated Na⁺ reabsorption. CCBs shift the curve by increasing renal blood flow and GFR. All effective antihypertensives ultimately work by shifting the renal pressure-natriuresis curve back toward normal.

Autoregulation — Protecting Organs from Pressure Fluctuations

The brain, heart, and kidneys autoregulate their blood flow — they maintain constant perfusion across a wide range of arterial pressures (~60–160 mmHg in the brain and kidney; ~50–120 mmHg in the coronary circulation). Autoregulation is mediated by: (1) the myogenic response (vascular smooth muscle contracts in response to stretch → increased resistance → maintains flow when pressure rises, and vice versa), and (2) metabolic factors (increased tissue metabolism → release of vasodilators — adenosine, K⁺, CO₂, lactate → vasodilation → increased flow to match demand). When MAP falls below the autoregulatory range (<60 mmHg for kidney and brain), blood flow becomes pressure-dependent → renal and cerebral hypoperfusion → acute kidney injury and neurological dysfunction.

Compensatory Mechanisms in Chronic Heart Failure: A Blood-Pressure Perspective

Neurohormonal Activation in CHF

Chronic heart failure is characterised by REDUCED cardiac output, which the body perceives as hypovolaemia (even though total blood volume may actually be INCREASED due to salt and water retention). The baroreflex responds to reduced arterial pressure by increasing sympathetic outflow and reducing vagal tone. Simultaneously, reduced renal perfusion activates the RAAS. These compensatory mechanisms, while initially adaptive (maintaining blood pressure and perfusion of vital organs), become maladaptive in the long term.

SYMPATHETIC OVERACTIVATION: Chronically elevated catecholamines → (1) downregulation and desensitisation of cardiac β1-receptors (reducing the heart's responsiveness to its own sympathetic drive — a protective mechanism that also limits the inotropic reserve), (2) direct cardiotoxicity (norepinephrine → Ca²⁺ overload → myocyte apoptosis and necrosis), (3) increased arrhythmia risk, and (4) peripheral vasoconstriction → increased afterload → further reduction in stroke volume. This is the rationale for β-blocker therapy in CHF (carvedilol in dogs) — they PROTECT the heart from its own sympathetic drive, even though they reduce contractility acutely.

RAAS OVERACTIVATION: Chronically elevated angiotensin II and aldosterone → (1) vasoconstriction → increased afterload, (2) sodium and water retention → increased preload → elevated filling pressures → pulmonary oedema, (3) cardiac and vascular fibrosis (angiotensin II stimulates TGF-β and connective tissue growth factor → fibroblast proliferation and collagen deposition → myocardial stiffness and impaired diastolic function), and (4) direct cardiotoxicity (angiotensin II → myocyte hypertrophy and apoptosis). This is the rationale for ACE inhibitor and aldosterone antagonist therapy in CHF — they BLOCK the maladaptive neurohormonal response.

The modern approach to canine CHF: combination therapy — an ACE inhibitor (enalapril or benazepril) to block RAAS, ± a β-blocker (carvedilol — titrated VERY slowly, starting at 0.05–0.1 mg/kg BID and increasing over WEEKS to target) to protect against sympathetic overdrive, ± spironolactone (aldosterone antagonist) to further block fibrosis and sodium retention, + furosemide as needed for congestion. The goal is NOT to normalise cardiac output — it is to manage congestion, slow disease progression, and improve quality of life.

Feline Hypertension and the Eye

The Retina as a Window to Hypertensive Target-Organ Damage

The retinal vasculature is uniquely vulnerable to hypertension because (1) retinal arterioles lack external elastic lamina (less structural support), (2) the retina has one of the highest oxygen consumptions per gram of any tissue, and (3) retinal vessels can be directly visualised — making the fundic examination a 'window' to hypertensive vascular damage throughout the body. Hypertensive retinopathy in cats manifests as: arteriolar tortuosity (earliest sign), retinal haemorrhages (flame-shaped or dot/blot), retinal oedema (grey, thickened retina), retinal detachment (focal or complete bullous detachment — the commonest cause of acute blindness in hypertensive cats), and papilloedema. The pathophysiology: sustained hypertension → arteriolar vasoconstriction (autoregulatory response) → eventually, autoregulation fails → arterioles dilate passively → increased hydrostatic pressure in the capillary bed → endothelial damage → plasma leakage (oedema) and RBC extravasation (haemorrhage) → if severe → serous retinal detachment. Treatment: amlodipine 0.625–1.25 mg/cat PO q24h. Blood pressure should be rechecked within 7 days — target systolic BP <160 mmHg. Retinal reattachment and vision recovery are possible within days to weeks of achieving normotension if the retina is not severely atrophic. The prognosis for vision is good if the retina is still attached at the time treatment is initiated; if the retina has been detached for more than 7–14 days, degeneration limits recovery.

The Renin-Angiotensin-Aldosterone System in the Feline Kidney

Chronic kidney disease (CKD) is the most common cause of feline hypertension. The failing kidney loses nephrons → remaining nephrons hyperfilter → increased glomerular capillary pressure → glomerular hypertension → further nephron loss → a vicious cycle. Angiotensin II constricts the EFFERENT arteriole more than the afferent arteriole → INCREASES glomerular capillary pressure → increases GFR in the short term (a compensatory mechanism) but at the cost of LONG-TERM glomerular damage (glomerulosclerosis). This is the rationale for ACE inhibitors and ARBs in CKD: by blocking angiotensin II-mediated efferent arteriolar constriction, they REDUCE glomerular capillary pressure → reduce proteinuria → slow the progression of CKD. The IRIS (International Renal Interest Society) staging system incorporates proteinuria (UPCR) and blood pressure into CKD staging, and recommends antihypertensive therapy when systolic BP >160 mmHg (risk of target-organ damage) or >150 mmHg with evidence of target-organ damage (proteinuria, retinopathy).

Pharmacology of Hypertension: Advanced Drug Targets

Amlodipine vs ACE Inhibitors — Choosing the Right Drug

The choice between amlodipine (calcium channel blocker) and an ACE inhibitor (enalapril, benazepril) or ARB (telmisartan) depends on the underlying disease and the presence of proteinuria: (1) FELINE HYPERTENSION: Amlodipine is first-line. It is highly effective (~90% achieve target BP), has minimal renal side effects, and is formulated in a palatable oral solution. If proteinuria (UPCR >0.4) coexists with hypertension → add telmisartan (Semintra — an ARB approved for feline CKD with proteinuria). The combination is synergistic: amlodipine reduces TPR (vasodilation), telmisartan reduces glomerular capillary pressure (efferent arteriole dilation → reduced proteinuria). (2) CANINE HYPERTENSION: ACE inhibitors (enalapril, benazepril) are first-line, particularly if proteinuria coexists (common in canine CKD). If BP remains uncontrolled on ACEi monotherapy → add amlodipine. (3) CANINE CHF: ACE inhibitors are first-line for their proven mortality benefit (enalapril in the COVE and LIVE trials) — they reduce afterload, preload, and cardiac fibrosis. Amlodipine is generally avoided in CHF because dihydropyridine CCBs can cause reflex sympathetic activation (baroreflex response to vasodilation → increased HR and contractility → increased myocardial O₂ demand).

Monitoring Therapy — How Often and What to Measure

Blood pressure should be measured using a consistent method (Doppler is preferred in conscious cats and small dogs; oscillometric in larger, calm dogs). Measure in a quiet room, with the animal acclimatised for 5–10 minutes. Take 5–7 readings, discard the first, and average the rest. Recheck BP 7–14 days after starting or adjusting antihypertensives. Once controlled, recheck every 3–6 months. In patients on ACE inhibitors or ARBs, monitor renal function (creatinine, BUN, electrolytes) — ACEi/ARBs can cause a modest, acceptable rise in creatinine (up to 30% from baseline) due to reduced glomerular capillary pressure. A rise >30% or development of hyperkalemia → reduce dose or discontinue. In patients on amlodipine, monitor for gingival hyperplasia (a recognised adverse effect in dogs — reported in up to 10% of dogs on chronic amlodipine — usually reversible on dose reduction or discontinuation).

Hypotension in Critical Care: Managing the Vasoplegic Patient

Vasodilatory Shock — When the Vasculature Loses Tone

Vasodilatory (distributive) shock — the haemodynamic profile of sepsis, anaphylaxis, and acute adrenal insufficiency — is characterised by profound vasodilation that renders endogenous vasoconstrictors and conventional-dose catecholamines ineffective. The pathophysiology: inflammatory mediators (TNF-α, IL-1, nitric oxide) → activation of ATP-sensitive K⁺ channels (K_ATP) in vascular smooth muscle → K⁺ efflux → hyperpolarisation → closure of voltage-gated Ca²⁺ channels → reduced intracellular Ca²⁺ → vasodilation. Additionally, inducible nitric oxide synthase (iNOS) produces massive quantities of NO → cGMP-mediated vasodilation. Vasopressin (ADH) deficiency develops because the neurohypophyseal stores of ADH are depleted within 24–48 hours of sustained hypotension → relative vasopressin deficiency → further loss of vascular tone.

Management of vasodilatory shock: (1) NOREPINEPHRINE (0.1–2 μg/kg/min IV CRI) — α1-agonist. First-line vasopressor. Increases TPR without significantly affecting HR (unlike dopamine, which causes tachycardia via β1). (2) VASOPRESSIN (0.5–2 mU/kg/min — 'low-dose vasopressin') — V1 receptor agonist. Restores vascular tone in vasopressin-deficient states. Synergistic with norepinephrine — often allows norepinephrine dose reduction ('catecholamine-sparing' effect). (3) ANGIOTENSIN II (synthetic human angiotensin II — recently approved for human vasodilatory shock; not yet available in veterinary medicine). (4) METHYLENE BLUE — inhibits guanylate cyclase → reduces cGMP → reduces NO-mediated vasodilation. Used as a rescue therapy in vasoplegic syndrome (post-cardiopulmonary bypass) — limited evidence in veterinary patients. (5) HYDROCORTISONE — 'stress-dose' steroids (1–2 mg/kg IV q6h) in catecholamine-resistant shock. Rationale: critical illness-related corticosteroid insufficiency (CIRCI) → inadequate cortisol response to stress → reduced vascular sensitivity to catecholamines. Steroids restore vascular catecholamine responsiveness. Controversial but widely used in both human and veterinary critical care.

The key principle: in vasodilatory shock, FLUIDS ALONE will not restore blood pressure — the vasculature is maximally dilated, and additional fluid simply extravasates into the interstitium (the glycocalyx is degraded → 'capillary leak'). Early initiation of vasopressors, titrated to MAP >65 mmHg (or systolic >90 mmHg), is essential. Monitor: continuous direct arterial blood pressure (gold standard), lactate clearance (marker of tissue perfusion), and urine output (target >1 mL/kg/h).

Frequently asked questions

Self-check quiz

Test yourself. Answers are below each question — cover them first if you are studying.